drug
emapalumab
Marketedupdated 5mo agoby Sobi Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 1all catalysts(0)
nothing on the calendar yet
Trials studying emapalumab
- phase3Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
- phase4A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
- phase2Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
- phase2A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
- EP1Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
- phase2Emapalumab Prevention of CAR-T Cell Associated Toxicities
- phase2A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- phase3Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
News(1)
- Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 pushSobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.fiercebiotech · 1mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that